Possible Role of Cytochromes P450 in Lupus Erythematosus and Related Disorders

Abstract

Cytochromes P450 comprise a superfamily of enzymes pivotal in the metabolism of innumerable substrates of both endogenous and exogenous origin. The total number of distinct P450 genes, each encoding a different enzyme in humans, is estimated to be at least 60 and possibly several hundred. The cytochrome P450 (CYP) superfamily nomenclature system is based on divergent evolution of the genes. Most of the enzymes within gene families CYP1, CYP2, CYP3 and CYP4 appear to have evolved as the body's primary defense against the onslaught of chemicals confronted on a daily basis. Whereas P450 enzymes more than 3.5 billion years ago were undoubtedly designed as necessary components of signal transduction pathways, in the past billion years most P450 enzymes have become generally responsible for the detoxification of numerous foreign chemicals. During such oxidative metabolism, it has become increasingly apparent that these enzymes are also capable of functioning in an ambivalent manner, generating toxic intermediates. More than a dozen human P450 polymorphisms have been characterized. Genetic variability in P450 expression is therefore likely to have significant bearing on individual susceptibility to chemical toxicity. In this review, genetic differences in human P450 expression are outlined, and their possible relationship to autoimmune disease is examined. In addition, the speculative role of P450 polymorphisms in several 'lupus-like' disorders is discussed.

Keywords

Cytochrome P450 SLE Lupus-like disorders

Get full access to this article

View all access options for this article.

References

Nebert DW Drug-metabolizing enzymes in ligand-modulated transcription. Biochem Pharmacol 1994; 47: 25-37.

Nebert DW , McKinnon RA Cytochrome P450: evolution and functional diversity. Progr Liver Dis 1994 (in press).

Nelson DR , Kamataki T. , Waxman DJ et al. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes and nomenclature. DNA Cell Biol 1993; 12: 1-51.

Nebert DW , Nelson DR , Coon MJ et al. The P450 superfamily: update on new sequences, gene mapping and recommended nomenclature. DNA Cell Biol 1991 ; 10: 1-14.

Gonzalez FJ , Nebert DW Evolution of the P450 gene superfamily: animal-plant 'warfare', molecular drive and human genetic differences in drug oxidation. Trends Genet 1990; 6: 182-7.

Meyer UA Genotype of phenotype: the definition of a pharmacogenetic polymorphism. Pharmacogenetics 1991; 1: 66-7.

Kellermann G. , Shaw CR , Luyten-Kellermann M. Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma. New Engl J Med 1973; 289: 934-7.

Hayashi S-I. , Watanabe J. , Nakachi K. , Kawajiri K. Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene. J Biochem (Tokyo) 1991; 110: 407-11.

Hayashi S-I. , Watanabe J. , Kawajiri K. High susceptibility to lung cancer analyzed in terms of combined genotypes of P450IA1 and muclass glutathione S-transferase genes. Jpn J Cancer Res 1993; 83: 866-70.

10.

Tefre T. , Ryberg D. , Haugen A. et al. Human CYP1A1 (cytochrome P1450) gene: lack of association between the MspI restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population. Pharmacogenetics 1991; 1: 20-5.

11.

Shields PG , Sugimura H. , Caporaso NE et al. Polycyclic aromatic hydrocarbon-DNA adducts and the CYP1A1 RFLP . Environ Health Perspect 1992; 98: 191-4.

12.

Hirvonen A. , Husgafvel-Pursainen K. , Karjalainen A. , Anttila S. , Vainio H. Point mutational MspI and Ile-Val polymorphisms closely linked in the cytochrome P450IA1 gene: lack of association with susceptibility to lung cancer in a Finnish study population. Cancer Epidemiol Biomark Prevent 1992; 1: 485-9.

13.

Nebert DW , Petersen DD , Puga A. Human AH locus polymorphism and cancer: inducibility of CYP1A1 and other genes by combustion products and dioxin. Pharmacogenetics 1991; 1: 68-78.

14.

Butler MA , Lang NP , Young JF et al. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992; 2: 116-27.

15.

Guenerich FP

Polymorphism of cytochrome P-450 in humans. Trends Pharmcol

Sci 1989; 10: 107-9.

16.

Gonzalez FJ , Meyer UA Molecular genetics of the debrisoquinsparteine polymorphism. Clin Pharmacol Ther 1991; 50: 233-8.

17.

Ingelman-Sundberg M. , Johansson I. , Persson I. et al. Genetic polymorphism of cytochromes P450: interethnic differences and relationship to incidence of lung cancer . Pharmacogenetics 1992; 2: 264-71.

18.

Nebert DW , Weber WW Pharmacogenetics. In: Principles of Drug Action, The Basis of Pharmacology, 3rd edn. Pratt WB , Taylor PW (eds). New York: Churchill Livingstone, 1990: 469-531.

19.

Beaune PH , Bourdi M. Autoantibodies against cytochromes P-450 in drug-induced autoimmune hepatitis . Ann N Y Acad Sci 1993; 685: 641-5.

20.

Winqvist O. , Gustafsson J. , Rorsman F. , Karlsson FA , Kämpe O. Two different cytochrome P450 enzymes are the adrenal antigens in autoimmune polyendocrine syndrome type I and Addison's disease. J Clin Invest 1993; 92: 2377-85.

21.

Manns MP , Griffin KJ , Quattrochi LC et al. Identification of cytochrome P-450IA2 as a human autoantigen . Arch Biochem Biophys 1990; 280:229-32.

22.

Bourdi M. , Larrey D. , Nataf J. et al. Anti-liver endoplasmic reticulum autoantibodies are directed against human cytochrome P-450 1A2. J Clin Invest 1990; 85: 1907-13.

23.

Poupon R. , Petit J. , Bodin F. , de Saint-Maur PP , Homberg JC , Damis F. , Hépatites chroniques: intérêt d'une classification fondée sur la présence ou l'absence de l'antigéne HBs, de l'anticorps antimuscle lisse et de l'anticorps anti-reticulum endoplasmique. Gastroenterol Clin Biol 1980; 4: 666-73.

24.

Homberg JC , André C. , Abuaf N. A new anti-liver-kidney microsome antibody (anti-LKM2) in tienilic acid-induced hepatitis. Clin Exp Immunol 1984; 55: 561-70.

25.

Beaune P. , Dansette PM , Mansuy D. et al. Human antimicrosome antibodies appearing in a drug induced hepatitis are directed against a cytochrome P-450 hydroxylating the drug. Proc Natl Acad Sci USA 1987; 84: 551-5.

26.

Meier UT , Meyer UA Genetic polymorphism of human cytochrome P-450 (S)-mephenytoin hydroxylase: studies with human autoantibodies suggest a functionally altered cytochrome P-450 isozyme as cause of the genetic deficiency. Biochemistry 1988; 26: 8466-74.

27.

Maggiore G. , Bernard O. , Homberg JC et al. Liver disease associated with anti-liver-kidney microsome antibody in children. J Pediatr 1986; 108: 399-404.

28.

Homberg JC , Abuaf N. , Bernard O. et al. Chronic active hepatitis associated with anti-liver/kidney microsome antibody type 1: a second type of 'autoimmune' hepatitis. Hepatology 1987; 7: 1333-9.

29.

Zanger UM , Hauri AP , Loeper J. , Homberg JC , Meyer UA Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II. Proc Natl Acad Sci USA 1988; 85: 8256-60.

30.

Gueguen M. , Meunier-Rotival M. , Bernard O. , Alvarez F. Anti-liverkidney microsome antibody recognizes a cytochrome P-450 from IID subfamily. J Exp Med 1988; 168: 801-6.

31.

Kiffel L. , Loeper J. , Homberg JC , Leroux JP A human cytochrome P-450 is recognized by and-liver/kidney microsome antibodies in autoimmune hepatitis. Biochem Biophys Res Commun 1989; 159: 283-8.

32.

Manns MP , Johnson EF , Griffin KJ , Tan EM , Sullivan KF Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is P-450db1. J Clin Invest 1989; 83: 1066-72.

33.

Kenna JG , Martin JL , Pohl LR The topography of trifluoroacetylated protein antigens in liver microsomal fractions from halothane treated rats. Biochem Pharmcacol 1992; 44: 621-9.

34.

Riley RJ , Smith G. , Wolf CR , Cook VA , Leeder JS Human anti-endoplasmic reticulum antibodies produced in aromatic anticonvulsant hypersensitivity reactions recognise rodent CYP3A proteins and a similarly regulated human P450 enzyme(s). Biochem Biophys Res Commun 1993; 191: 32-40. [Published erratum appears in Biochem Biophys Res Commun 1993; 191: 585.]

35.

Loeper J. , Descatoire V. , Maurice M. et al. Cytochromes P-450 in human hepatocyte plasma membrane: recognition by several autoantibodies. Gastroenterology 1993; 104: 203-16.

36.

Hess EV Role of drugs and environmental agents in lupus syndromes. Curr Opin Rheumatol 1992; 4: 688-92.

37.

Meggs WJ Neurogenic inflammation and sensitivity to environmental chemicals. Environ Health Perspect 1993; 101: 234-8.

38.

Humbert R. , Adler DA , Disteche CM , Hassett C. , Omiecinski CJ , Furlong CF The molecular basis of the human serum paraoxonase activity polymorphism. Nature Genet 1993; 3: 73-6.